secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001193125-23-036052
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara supplements merger proxy with lawsuit update and executive compensation details
--------------------------------------------------------------------------------

- Lawsuit filed Nov 23, 2022 voluntarily dismissed Jan 19, 2023; Imara says meritless.
- Pipeline chart updated: ELVN-002 advanced to Phase 1 clinical trial.
- SVB Securities received $2.2M fees from Imara in past 2 years; disclosed as supplemental.
- Post-merger: Kintz base salary to $550K, Collins to $465K, Hohl to $410K; bonus targets increased.
- Enliven executives to receive change-in-control severance with 12-18 months salary and equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523036052/0001193125-23-036052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523036052/d410339d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-036052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer